Trifocal MICS IOL

Article

Carl Zeiss is set to unveil the AT LISA tri 839MP IOL at the ESCRS this year in Milan. The AT LISA enables patients to switch between near, intermediate and far distance visions without the need for corrective spectacles.

Carl Zeiss is set to unveil the AT LISA tri 839MP IOL at the ESCRS this year in Milan.

The AT LISA enables patients to switch between near, intermediate and far distance visions without the need for corrective spectacles.

AT LISA tri provides asymmetrical light distribution between 50% far vision, 20% intermediate and 30% near vision. Light energy transmittance is increased for maintained contrast sensitivity and lower visual disturbance, resulting in significantly less halos and glare. Intermediate performance is enhanced due to the additional +1.66 diopters, compared to bifocal or convoluted trifocal IOLs.

The IOL can be used in conjunction with micro-incision cataract surgery (MICS) to lower the risk of astigmatism and reduce higher order aberrations. AT LISA tri can be safely implanted through an incision of 1.8 mm when used with the BLUEMIXS 180 injector. The anti-posterior capsular opacification (PCO) profile of the lens reinforces the effect of the square edges for effective prevention of PCO.

Booth number: S117
Website:www.meditec.zeiss.com/escrs

Please note this product may not be FDA-approved for the US.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.